The rebounded epidemic has caused short supply of betadex sulfobutyl ether sodium

Home > Application > Application > The rebounded epidemic has caused short supply of betadex sulfobutyl ether sodium

The rebounded epidemic has caused short supply of betadex sulfobutyl ether sodium

Since April this year, the epidemic in India has been severely out of control. The number of confirmed cases of new coronavirus infections for several days has exceeded 200,000. This has led to an extreme shortage of antiviral drugs in the Indian market. The Indian government recently issued an indefinite period of antiviral drug Remdesivir. The export ban continues until the epidemic eases or is lifted. Remdesivir is the only drug approved by the FDA for the treatment of COVID-19 in 2020. Major Indian pharmaceutical companies are producing remdesivir injections at full capacity, which has led to a surge in demand for sulfobutyl beta cyclodextrin sodium (SBECD), an excipient for remdesivir. In order to meet the needs of the market and help fight the epidemic, as a rare betadex sulfobutyl ether sodium(SBECD) manufacturer, we have a heavy responsibility and urgent production. At present, we are focusing on the production of sulfobutyl beta cyclodextrin sodium SBECD across the board.

Betadex sulfobutyl ether sodium (SBECD)  is a cyclodextrin derivative with high safety and good solubilizing effect. It can improve the solubility, bioavailability and stability of the drug. It is widely used in injection drugs solubilization. Zhiyuan Biotech, a company specializing in the production of cyclodextrin derivatives, takes the exploration of the unlimited applications of cyclodextrin in human life as its corporate vision, and strives to contribute its strength to the development of new materials and new technologies for mankind.

For more information about cyclodextrin, please contact: 


Hot Products

  • wechat

    15628927619: 15628927619

Chatting

Contact Us